Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial

Selinger, Christian P.; Bell, Andrew; Cairns, Alastair; Lockett, MJ; Sebastian, Shaji; Haslam, Neil

doi:10.1016/j.jhin.2013.02.019

Cited by 77 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, this dosage was shown to be optimal in previous mouse colitis studies (30,48). For humans, a daily average dosage 4 3 10 11 to 9 3 10 11 CFU is recommended for both dietary management and ulcerative colitis (49,50). This means that, corrected for body weight, the dosages are in the same order of magnitude.…”

Section: Discussionmentioning

confidence: 92%

The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice

Mariman

Tielen

Koning

et al. 2015

The Journal of Nutrition

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice

Mariman

Tielen

Koning

et al. 2015

The Journal of Nutrition

View full text Add to dashboard Cite

show abstract

“…Furthermore, effects of probiotics have been examined in clinical studies for a number of gastrointestinal diseases. For instance, randomized trials suggest that co-administration of VSL#3, a probiotic compound consisting of eight different bacterial strains [21], or Saccharomyces boulardii [22] significantly decrease the incidence of antibiotics associated diarrhea (AAD). Moreover, episodes of infectious diarrhea in both adults and children can be shortened by the use of probiotics [23].…”

Section: Introductionmentioning

confidence: 99%

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment

et al. 2017

View full text Add to dashboard Cite

BackgroundThe incidence of human Campylobacter jejuni infections is progressively increasing worldwide. Probiotic compounds might open up valuable tools to decrease pathogen burden and subsequent pro-inflammatory immune responses, but in vivo data are scarce.Methods and resultsSecondary abiotic mice generated by broad-spectrum antibiotic treatment were perorally challenged with the commercial probiotic compound VSL#3 consisting of Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii ssp. bulgaricus) either 5 days before (i.e. prophylactic regimen) or after (i.e. therapeutic regimen) peroral C. jejuni strain 81–176 infection, and analyzed 3 weeks following the initial bacterial re-association. Upon challenge, mice were colonized with the probiotic bacteria and/or C. jejuni at comparable intestinal loads, but co-colonization did not result in reduction of the pathogen burden. Remarkably, prophylactic as well as therapeutic VSL#3 treatment of C. jejuni infected mice ameliorated intestinal apoptosis and pro-inflammatory immune responses as indicated by lower numbers of innate and adaptive immune cell populations in the murine colon upon probiotic prophylaxis or treatment and reduced colonic concentrations of pro-inflammatory mediators including IL-6 and MCP-1. Importantly, concentrations of anti-inflammatory mediators such as IL-10 were significantly elevated in the colon of probiotics treated mice as compared to untreated controls. Strikingly, prophylactic VSL#3 treatment attenuated C. jejuni induced systemic pro-inflammatory responses as indicated by less TNF and IL-12p70 secretion in the spleen of VSL#3 pre-treated as compared to non-treated mice.ConclusionAdministration of probiotic formulations such as VSL#3 might open up valuable strategies for prophylaxis and/or treatment of C. jejuni induced intestinal and systemic sequelae in vivo by the suppression of pro-inflammatory and induction of anti-inflammatory responses.

show abstract

“…A 2013 RCT conducted in 229 adult inpatients showed that compared with placebo, administration of a VSL#3 mixture reduced the risk of antibiotic-associated diarrhea; however, the difference between groups was significant only in the per protocol analysis (11.4 vs. 0%, respectively; RR 0.04, 95% CI 0.00-0.59) and not in the intention-to-treat analysis (8.9 vs. 4.3%, respectively; RR 1.91, 95% CI 0.68-5.43) [45]. …”

Section: Bacterial Probioticsmentioning

confidence: 99%

Probiotic Bacterial and Fungal Strains: Claims with Evidence

Szajewska

Konarska²,

Kołodziej³

2016

Dig Dis

View full text Add to dashboard Cite

Background: Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit for the host. This review summarizes current (i.e. published in the last 5 years) key evidence on probiotic efficacy and its safety in adults and children. To identify relevant data, searches of MEDLINE and the Cochrane Library databases were performed in August 2015 to locate randomized controlled trials (RCTs) or their meta-analyses. The focus was on commonly used, well-specified, bacterial and yeast probiotics for the treatment of gastrointestinal disorders. The MEDLINE database was also searched for evidence-based clinical practice guidelines, developed by scientific societies in the same timeframe. Data on safety of probiotics were obtained from a document developed by the US Agency for Healthcare Research and Quality. Key Messages: A number of relevant RCTs and meta-analyses are available. Saccharomyces boulardii is the most studied yeast probiotic, and Lactobacillus rhamnosus GG is the most studied bacterial probiotic. For both, the best documented fact is their efficacy for the treatment of acute gastroenteritis, especially in children, and for the prevention of antibiotic-associated diarrhea, both in adults and children. There is some evidence to support the use of probiotics to prevent or treat other diseases, such as necrotizing enterocolitis, infantile colic, Helicobacter pylori infection, and irritable bowel syndrome, but further studies are needed to identify which strain(s) is/are the most effective. Data on safety, particularly long-term safety, are limited. The risk of side effects is greater in people who have severe underlying health conditions. Conclusions: The evidence on bacterial and yeast probiotics has considerably expanded during recent years. Accumulated data allow one to make informed decisions about the effectiveness of probiotics and about how to reduce the use of those without proven efficacy.

show abstract

Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial

Cited by 77 publications

References 16 publications

The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice

The Probiotic Mixture VSL#3 Has Differential Effects on Intestinal Immune Parameters in Healthy Female BALB/c and C57BL/6 Mice

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment

Probiotic Bacterial and Fungal Strains: Claims with Evidence

Contact Info

Product

Resources

About